Antibody developers are increasingly utilising antibody libraries to derive high-quality, drug-like biologics To target hard-to-drug targets like G protein-coupled receptors (GPCRs), more libraries, including better

CHOP apoptosis signaling improved ESS symptoms, and the targeted deletion of β-arrestin2 significantly increased